N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease

Hepatitis Monthly

Volumn 10, Issue 1, 2010, Pages 12-16

  Khoshbaten, Manouchehr ^a   Aliasgarzadeh, Akbar ^b   Masnadi, Koorosh ^a   Tarzamani, Mohammad K ^b   Farhang, Sara ^c   Babaei, Hosain ^b   Kiani, Javad ^b   Zaare, Maryam ^b   Najafipoor, Farzad ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

N acetylcysteine; Non alcoholic fatty liver disease; Therapy

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; PATIENT SELECTION; PORTAL VEIN; REPEAT PROCEDURE; SPLEEN; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN DIAMETER;

EID: 77949730007     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
2. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356-62.
3. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485-90.
4. Oliveira CP, Gayotto LC, Tatai C, et al. Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats. Nutr J. 2003;2:9.
5. Attri S, Rana SV, Vaiphie K, et al. Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. Indian J Exp Biol. 2001;39(5):436-40.
6. Caglikulekci M, Dirlik M, Pata C, et al. Effect of N-acetylcysteine on blood and tissue lipid peroxidation in lipopolysaccharide- induced obstructive jaundice. J Invest Surg. 2006;19(3):175-84.
7. Huang H, Yin R, Zhu J, et al. Protective effects of melatonin and N-acetylcysteine on hepatic injury in a rat cardiopulmonary bypass model. J Surg Res. 2007;142(1):153-61.
8. Terneus MV, Kiningham KK, Carpenter AB, Sullivan SB, Valentovic MA. Comparison of S-Adenosyl-L-methionine and N-acetylcysteine protective effects on acetaminophen hepatic toxicity. J Pharmacol Exp Ther. 2007;320(1):99-107.
9. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13(38):5127-32.
10. de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with nonalcoholic steatohepatitis. Hepatol Res. 2008;38(2):159-65.
11. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27-41.
12. Starkel P, Sempoux C, Leclercq I, et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol. 2003;39(4):538-46.
13. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007(1):CD004996.
14. de Oliveira CP, Simplicio FI, de Lima VM, et al. Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats. World J Gastroenterol. 2006;12(12): 1905-11.
15. Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Patumraj S, Klaikeaw N. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. J Med Assoc Thai. 2007;90(4):788-97.
16. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73.
17. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22(6):437-43.
18. Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci. 2000;45(1):196-200.